Authors reply: an adjusted indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory metastatic renal cell carcinoma patients using repeated matched samples

By Di Lorenzo Giuseppe   Casciano Roman   Malangone Elisabetta   Buonerba Carlo   Sherman Steven   Willet Jacob   Wang Xufang   Liu Zhimei   De Placido Sabino  

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 7, 2012-05 ,pp. : 1079-1080

Informa Healthcare

Access to resources Recommend Favorite

An indirect comparison of everolimus versus sorafenib in metastatic renal cell carcinoma – a flawed analysis?

By Hoaglin David C   Cislo Paul R  

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 7, 2012-05 ,pp. : 1077-1078

Informa Healthcare

Access to resources Recommend Favorite

An indirect comparison of everolimus versus sorafenib in metastatic renal cell carcinoma - a flawed analysis and a problematic response

By Hoaglin David C  

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 12, 2013-08 ,pp. : 1705-1706

Informa Healthcare

Access to resources Recommend Favorite

Sequential therapy with sunitinib and sorafenib in metastatic hepatocellular carcinoma

By Ahn Hee  

Investigational New Drugs, Vol. 30, Iss. 4, 2012-08 ,pp. : 1768-1772

Springer Publishing Company

Access to resources Recommend Favorite

Reflex sympathetic dystrophy in patients with metastatic renal cell carcinoma treated with Everolimus

By Massard Christophe   Fizazi Karim   Gross-Goupil Marine   Escudier Bernard  

Investigational New Drugs, Vol. 28, Iss. 6, 2010-12 ,pp. : 879-881

Springer Publishing Company

Access to resources Recommend Favorite